Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.
copy number assay
immunohistochemistry
mutation analysis
peripheral T-cell lymphoma
telomerase reverse transcriptase
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
17
06
2021
received:
11
04
2021
accepted:
31
07
2021
pubmed:
4
9
2021
medline:
3
3
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activation of telomerase. We performed a molecular and pathological analysis of the TERT against three different peripheral T-cell lymphoma (PTCL) subtypes: PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and adult T-cell leukemia/lymphoma (ATLL). Immunohistochemical analysis demonstrated TERT expression in 31% of AITL, 11% of PTCL-NOS, and 5% of ATLL. Among them, AITL frequently showed high TERT expression with statistical significance. TERT promoter mutation analysis and genomic copy number evaluation were performed. TERT promoter mutation was observed in two cases of PTCL-NOS (2/40) and not in other PTCLs. Genome copy number amplification was detected in 33% of PTCL-NOS, 33% of AITL, and 50% of ATLL cases. We evaluated the relationship between the analyzed TERT genomic abnormalities and protein expression; however, no apparent relationship was observed. Furthermore, immunostaining showed TERT expression in the PTCL cytoplasm, suggesting the existence of mechanisms other than the maintenance of telomere length. Statistical analysis of the effect of TERT expression on the prognosis in PTCL cases revealed that TERT expression tended to have a poor prognosis in PTCL-NOS. Since TERT expression was not an independent factor in multivariate analysis, further research will be needed to clarify the poor prognosis of PTCL-NOS in TERT expression.
Identifiants
pubmed: 34477310
doi: 10.1002/cam4.4200
pmc: PMC8495278
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6786-6794Subventions
Organisme : Grant-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science, and Technology of Japan
ID : 17K08751
Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Cell. 2018 Feb 12;33(2):259-273.e7
pubmed: 29398449
Blood. 2014 Sep 4;124(10):1570-7
pubmed: 25006130
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Leuk Lymphoma. 2014 Sep;55(9):2038-47
pubmed: 24180328
J Hematol Oncol. 2011 Aug 15;4:34
pubmed: 21843362
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11091-4
pubmed: 7479943
Sci Rep. 2016 Nov 11;6:36990
pubmed: 27833153
Mod Pathol. 2021 Feb;34(2):314-326
pubmed: 32973330
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20388-93
pubmed: 21730156
Am J Hematol. 2016 May;91(5):481-5
pubmed: 26852175
Hum Pathol. 2018 Sep;79:86-92
pubmed: 29775622
Nat Commun. 2013;4:2185
pubmed: 23887589
Genes (Basel). 2016 Jul 18;7(7):
pubmed: 27438857
Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Elife. 2015 Jul 21;4:
pubmed: 26194807
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Cancer Sci. 2008 Jun;99(6):1092-9
pubmed: 18482052
Nat Genet. 2014 Apr;46(4):371-5
pubmed: 24584070
Leuk Lymphoma. 2013 Nov;54(11):2392-8
pubmed: 23410100
Neuro Oncol. 2015 Jan;17(1):45-52
pubmed: 25140036
Genes (Basel). 2016 Oct 25;7(11):
pubmed: 27792139
Haematologica. 2019 Aug;104(8):1626-1632
pubmed: 30630986
Cancer Sci. 2021 Apr;112(4):1339-1347
pubmed: 33576080
Blood. 2018 Aug 30;132(9):935-947
pubmed: 29769264
Br J Haematol. 2014 Feb;164(4):536-45
pubmed: 24245986
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Retrovirology. 2007 Dec 13;4:92
pubmed: 18078517
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Endocr Relat Cancer. 2014 May 06;21(3):427-34
pubmed: 24803525
J Am Acad Dermatol. 2019 Mar;80(3):660-669.e6
pubmed: 30165166
J Immunol. 2001 Apr 15;166(8):4826-30
pubmed: 11290757
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Cancer Med. 2021 Oct;10(19):6786-6794
pubmed: 34477310
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
J Immunol. 2000 Aug 1;165(3):1191-6
pubmed: 10903716
Oncotarget. 2015 Aug 14;6(23):19542-51
pubmed: 26143634
Oncogene. 2011 Mar 24;30(12):1379-89
pubmed: 21119600
Nature. 2009 Sep 10;461(7261):230-5
pubmed: 19701182
Haematologica. 2011 Nov;96(11):1636-43
pubmed: 21859738
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Immunol. 1999 Apr 15;162(8):4521-6
pubmed: 10201990
Cancer Med. 2018 Nov;7(11):5843-5858
pubmed: 30311404
Cancer Discov. 2016 Jun;6(6):584-93
pubmed: 27029895
Virchows Arch. 2017 Nov;471(5):659-666
pubmed: 28940014
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Nat Genet. 1999 Jan;21(1):115-8
pubmed: 9916803
Front Immunol. 2020 Nov 19;11:589929
pubmed: 33329574
Mol Cell Biol. 2016 Mar 31;36(8):1248-59
pubmed: 26830230
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132
pubmed: 28623509
Blood. 2016 Sep 8;128(10):1374-81
pubmed: 27418641
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Cancer Res. 2000 Nov 15;60(22):6230-5
pubmed: 11103775
Blood. 2019 Dec 12;134(24):2159-2170
pubmed: 31562134
Int J Lab Hematol. 2020 Dec;42(6):842-848
pubmed: 32744749
Nat Rev Immunol. 2002 Sep;2(9):699-706
pubmed: 12209138
Hematol Oncol. 2020 Dec;38(5):680-688
pubmed: 32569413
Nature. 1990 May 31;345(6274):458-60
pubmed: 2342578
Nat Rev Drug Discov. 2006 Jul;5(7):577-84
pubmed: 16773071